Itraconazole with standard treatment for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the antifungal drug itraconazole to the usual chemotherapy and radiation before surgery can improve the chance of no cancer cells remaining at surgery. It is for patients with esophageal or gastroesophageal junction cancer that can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with esophageal cancer or cancer at the junction of the stomach and esophagus.
- Your doctor has said the cancer can be removed with surgery.
- You plan to receive chemotherapy and radiation (or chemotherapy plus immunotherapy) before surgery.
- You are well enough to be up and about (able to care for yourself, but not necessarily able to do heavy physical work).
- Your kidney and liver function are within acceptable limits as judged by your doctor.
- You are not allergic to itraconazole.
- If you can become pregnant, you must have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the antifungal drug itraconazole to standard ablation therapy can help prevent esophageal cancer in people with high-risk Barrett's esophagus. You must have a confirmed diagnosis of Barrett's esophagus with low- or high-grade dysplasia or early-stage cancer, and be planning to have ablation treatment.
This trial tests whether giving a new immunotherapy drug (ivonescimab) along with standard chemotherapy before surgery can improve outcomes for people with resectable esophageal cancer. The goal is to shrink the tumor and increase the chance of successful surgery.
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
This trial tests a new drug called Ivonescimab (AK112) combined with two chemotherapy drugs (Abraxane and cisplatin) given before surgery for esophageal cancer. The goal is to see if this combination can shrink tumors and improve surgery outcomes for patients with locally advanced disease.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.